Targeting Antigens to Dendritic Cell Receptors for Vaccine Development

被引:121
作者
Apostolopoulos, Vasso [1 ,2 ]
Thalhammer, Theresia [3 ]
Tzakos, Andreas G. [4 ]
Stojanovska, Lily [2 ]
机构
[1] VA Consulting Serv, Melbourne, Vic, Australia
[2] Victoria Univ, Coll Hlth & Biomed, Melbourne, Vic, Australia
[3] Med Univ Vienna, Ctr Pathophysiol Immunol & Infectiol, Inst Pathophysiol & Allergy Res, Vienna, Austria
[4] Univ Ioannina, Dept Chem, Ioannina, Greece
关键词
D O I
10.1155/2013/869718
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Dendritic cells (DCs) are highly specialized antigen presenting cells of the immune system which play a key role in regulating immune responses. Depending on the method of antigen delivery, DCs stimulate immune responses or induce tolerance. As a consequence of the dual function of DCs, DCs are studied in the context of immunotherapy for both cancer and autoimmune diseases. In vaccine development, a major aim is to induce strong, specific T-cell responses. This is achieved by targeting antigen to cell surface molecules on DCs that efficiently channel the antigen into endocytic compartments for loading onto MHC molecules and stimulation of T-cell responses. The most attractive cell surface receptors, expressed on DCs used as targets for antigen delivery for cancer and other diseases, are discussed.
引用
收藏
页数:22
相关论文
共 221 条
[1]
Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells [J].
Aanoudse, Corlien A. ;
Bax, Marieke ;
Sanchez-Hernandez, Marta ;
Garcia-Vallejo, Juan J. ;
van Kooyk, Yvette .
INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (04) :839-846
[2]
ABRAHAM R, 1995, J IMMUNOL, V154, P1
[3]
Mannosylated Mucin-Type Immunoglobulin Fusion Proteins Enhance Antigen-Specific Antibody and T Lymphocyte Responses [J].
Ahlen, Gustaf ;
Strindelius, Lena ;
Johansson, Tomas ;
Nilsson, Anki ;
Chatzissavidou, Nathalie ;
Sjoblom, Magnus ;
Rova, Ulrika ;
Holgersson, Jan .
PLOS ONE, 2012, 7 (10)
[4]
Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters [J].
Akiyama, Y ;
Maruyama, K ;
Nara, N ;
Hojo, T ;
Cheng, JY ;
Mori, T ;
Wiltrout, RH ;
Yamaguchi, K .
CANCER LETTERS, 2002, 184 (01) :37-47
[5]
C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans [J].
Alvarez, CP ;
Lasala, F ;
Carrillo, J ;
Muñiz, O ;
Corbí, AL ;
Delgado, R .
JOURNAL OF VIROLOGY, 2002, 76 (13) :6841-6844
[6]
Apostolopoulos V., 2001, Current Molecular Medicine (Hilversum), V1, P469, DOI 10.2174/1566524013363645
[7]
Peptide mimics of a tumor antigen induce functional cytotoxic T cells [J].
Apostolopoulos, V ;
Lofthouse, SA ;
Popovski, V ;
Chelvanayagam, G ;
Sandrin, MS ;
McKenzie, IFC .
NATURE BIOTECHNOLOGY, 1998, 16 (03) :276-280
[8]
Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses [J].
Apostolopoulos, V ;
Pouniotis, DS ;
van Maanen, PJ ;
Andriessen, RW ;
Lodding, J ;
Xing, PX ;
McKenzie, IFC ;
Loveland, BE ;
Pietersz, GA .
VACCINE, 2006, 24 (16) :3191-3202
[9]
MUC1 cross-reactive Galα(1,3)Gal antibodies in humans switch immune responses from cellular to humoral [J].
Apostolopoulos, V ;
Osinski, C ;
McKenzie, IFC .
NATURE MEDICINE, 1998, 4 (03) :315-320
[10]
Cell-mediated immune responses to MUC1 fusion protein coupled to mannan [J].
Apostolopoulos, V ;
Pietersz, GA ;
McKenzie, IFC .
VACCINE, 1996, 14 (09) :930-938